Contact Us: 01282 426380
KM Financial Solutions | UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years
44721
post-template-default,single,single-post,postid-44721,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years

13 Jun UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years

Posted at 18:53h in News by
0 Likes
Bluebird bio Inc on Friday set
a price for its gene therapy, Zynteglo, at 1.58 million euros
($1.78 million) over five years, after winning conditional
approval in Europe this month to treat a rare genetic blood
disorder.
The company proposed an installment plan, with 315,000 euros
paid up front and four additional annual payments due only if
the treatment continues to be effective.

No Comments

Sorry, the comment form is closed at this time.